Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00232258 | Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study | PHASE2 | COMPLETED | 307 | — | — | Apr 1, 2005 | Sep 1, 2006 | Dec 10, 2008 | 14 | Argentina, Belgium +12 |
| Name | Type | Description |
|---|---|---|
| Nolpitantium besylate | DRUG | - |
Inclusion Criteria: * Age at least 18 years * Ulcerative colitis of at least 6 months duration * Patient's ulcerative colitis should remain active while taking 5-ASA or sulfasalazine for at least 4 week * If taking corticosteroids, dose must be stable for at least 2 weeks prior to enrollment and no...